Acurx Pharmaceuticals (ACXP) Current Assets (2021 - 2025)

Acurx Pharmaceuticals (ACXP) has reported Current Assets for 5 consecutive years, with $6.2 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Current Assets changed N/A year-over-year to $6.2 million; the trailing twelve-month figure through Jun 2025 stood at $6.2 million (changed N/A YoY), and the FY2024 full-year result was $3.9 million, down 49.96% from the prior year.
• Current Assets rose to $6.2 million in Q2 2025 per ACXP's latest filing, from $4.8 million in the prior quarter.
• Across five years, Current Assets topped out at $13.3 million in Q4 2021 and bottomed at $3.9 million in Q4 2024.
• Historically, Current Assets has averaged $7.9 million across 5 years, with a median of $7.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Assets climbed 0.29% in 2023, then slumped 49.96% in 2024.
• Over 5 years, Current Assets stood at $13.3 million in 2021, then declined by 29.25% to $9.4 million in 2022, then fell by 17.78% to $7.7 million in 2023, then plunged by 49.96% to $3.9 million in 2024, then soared by 59.61% to $6.2 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $6.2 million, $4.8 million, and $3.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.